• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

切除的无功能性胰腺神经内分泌肿瘤术后监测的合理方法。

A rational approach to postoperative surveillance for resected non-functional pancreatic neuro-endocrine tumours.

机构信息

Department of Hepatobiliary Surgery, Hepatopancreatobiliary (HPB) Surgical Unit, Addenbrooke's Hospital, Cambridge, UK.

Department of Statistics, University of Cambridge, UK.

出版信息

Pancreatology. 2019 Oct;19(7):1000-1007. doi: 10.1016/j.pan.2019.08.005. Epub 2019 Aug 16.

DOI:10.1016/j.pan.2019.08.005
PMID:31445889
Abstract

BACKGROUND

Non-functional pancreatic neuroendocrine tumours (NF-PNETs) are rare and have highly variable outcomes. Current guidelines recommend surveillance for NF-PNETs <2 cm. Patients who ultimately have surgical resection are at risk of disease recurrence, and data to support postoperative surveillance protocols are lacking. The aims of this study were to i) identify post-operative predictors of recurrence and ii) risk stratify patients at risk of recurrence.

METHODS

Consecutive patients who underwent surgery for NF-PNETs between 2002 and 2015 were identified retrospectively. Data were collected on demographics, pre-operative laboratory results and histopathological tumour characteristics. Statistical analyses were based on penalised Cox-regression modelling and a decision-tree model. Comparison of the variables identified was performed using ROC curves to identify the most sensitive and specific variable associated with disease recurrence.

RESULTS

We identified 73 patients (38 males) with a median age of 61.5 years (range: 31-79). The median period of follow-up was 49 months (5-131). During follow up, 10 deaths (13.9%) were recorded and disease recurrence occurred in 12 patients (16.4%). The Kaplan-Meier predicted 1-,3- and 5-year recurrence-free survival rates were 98.6% (95% CI = 95.9, 100%), 85.4% (76.9-94.8%) and 72% (58.7-88.2%) respectively. Cox multivariate analysis identified poor tumour differentiation (WHO G3 grade) and lymph node ratio (LNR) as independent predictors for recurrence (p < 0.05). A simple criterion of 'tumour grade G3 or LNR ≥0.1' was found to be sensitive and specific in detecting disease recurrence.

CONCLUSION

Our results have identified a simple and sensitive criterion for risk stratifying post-resection surveillance. Prospective validation in larger patient cohort is now warranted.

摘要

背景

无功能性胰腺神经内分泌肿瘤(NF-PNETs)较为罕见,且其结局具有高度异质性。目前的指南建议对直径<2cm 的 NF-PNET 进行监测。最终接受手术切除的患者有疾病复发的风险,且缺乏支持术后监测方案的数据。本研究旨在:i)确定术后复发的预测因素;ii)对有复发风险的患者进行风险分层。

方法

回顾性分析 2002 年至 2015 年间行手术治疗的 NF-PNET 连续患者。收集人口统计学、术前实验室检查结果和组织病理学肿瘤特征等数据。统计分析基于惩罚 Cox 回归模型和决策树模型。使用 ROC 曲线比较确定与疾病复发相关的最敏感和最特异的变量。

结果

共纳入 73 例患者(38 例男性),中位年龄为 61.5 岁(范围:31-79)。中位随访时间为 49 个月(5-131)。随访期间,记录到 10 例死亡(13.9%)和 12 例疾病复发(16.4%)。Kaplan-Meier 预测的 1、3 和 5 年无复发生存率分别为 98.6%(95%CI=95.9,100%)、85.4%(76.9-94.8%)和 72%(58.7-88.2%)。Cox 多变量分析发现肿瘤分化不良(WHO G3 级)和淋巴结比值(LNR)是复发的独立预测因素(p<0.05)。发现“肿瘤分级 G3 或 LNR≥0.1”的简单标准对检测疾病复发具有较高的敏感性和特异性。

结论

本研究结果确定了一种简单而敏感的术后监测风险分层标准。目前需要在更大的患者队列中进行前瞻性验证。

相似文献

1
A rational approach to postoperative surveillance for resected non-functional pancreatic neuro-endocrine tumours.切除的无功能性胰腺神经内分泌肿瘤术后监测的合理方法。
Pancreatology. 2019 Oct;19(7):1000-1007. doi: 10.1016/j.pan.2019.08.005. Epub 2019 Aug 16.
2
A Prognostic Scoring System for the Prediction of Metastatic Recurrence Following Curative Resection of Pancreatic Neuroendocrine Tumors.一种用于预测胰腺神经内分泌肿瘤根治性切除术后转移复发的预后评分系统。
J Gastrointest Surg. 2019 Jul;23(7):1392-1400. doi: 10.1007/s11605-018-4011-7. Epub 2018 Oct 23.
3
Malignant pancreatic neuroendocrine tumour: lymph node ratio and Ki67 are predictors of recurrence after curative resections.胰腺恶性神经内分泌肿瘤:淋巴结比值和 Ki67 是根治性切除术后复发的预测因素。
Eur J Cancer. 2012 Jul;48(11):1608-15. doi: 10.1016/j.ejca.2011.10.030. Epub 2011 Nov 28.
4
Analysis of recurrence after resection of well-differentiated non-functioning pancreatic neuroendocrine tumors.高分化无功能性胰腺神经内分泌肿瘤切除术后复发情况分析
Medicine (Baltimore). 2020 Jun 12;99(24):e20324. doi: 10.1097/MD.0000000000020324.
5
Management and outcomes of patients for non-functioning pancreatic neuroendocrine tumours: a multi-institutional analysis.无功能性胰腺神经内分泌肿瘤患者的管理与结局:多机构分析。
ANZ J Surg. 2022 Apr;92(4):787-793. doi: 10.1111/ans.17326. Epub 2021 Nov 1.
6
Evaluation of Outcomes Following Surgery for Locally Advanced Pancreatic Neuroendocrine Tumors.局部进展期胰腺神经内分泌肿瘤手术治疗效果评价。
JAMA Netw Open. 2020 Nov 2;3(11):e2024318. doi: 10.1001/jamanetworkopen.2020.24318.
7
Surveillance and comparison of surgical prognosis for asymptomatic and symptomatic non-functioning pancreatic neuroendocrine tumors.无症状和有症状非功能性胰腺神经内分泌肿瘤的手术预后监测和比较。
Int J Surg. 2017 Mar;39:127-134. doi: 10.1016/j.ijsu.2017.01.088. Epub 2017 Jan 27.
8
Optimal surgical management of unifocal vs. multifocal NF-PNETs: a respective cohort study.单灶性与多灶性神经内分泌胰腺肿瘤的最佳手术管理:一项队列研究。
World J Surg Oncol. 2024 Apr 26;22(1):115. doi: 10.1186/s12957-024-03383-9.
9
The conundrum of < 2-cm pancreatic neuroendocrine tumors: A preoperative risk score to predict lymph node metastases and guide surgical management.2cm 以下胰腺神经内分泌肿瘤的难题:预测淋巴结转移和指导手术管理的术前风险评分。
Surgery. 2019 Jul;166(1):15-21. doi: 10.1016/j.surg.2019.03.008. Epub 2019 May 6.
10
The role of lymph node ratio in recurrence after curative surgery for pancreatic endocrine tumours.淋巴结比率在胰腺内分泌肿瘤根治性手术后复发中的作用。
Pancreatology. 2013 Nov-Dec;13(6):589-93. doi: 10.1016/j.pan.2013.09.001. Epub 2013 Sep 19.

引用本文的文献

1
Predictors of disease recurrence after curative surgery for nonfunctioning pancreatic neuroendocrine neoplasms (NF-PanNENs): a systematic review and meta-analysis.功能性胰腺神经内分泌肿瘤(NF-PanNENs)根治性手术后疾病复发的预测因素:系统评价和荟萃分析。
J Endocrinol Invest. 2022 Apr;45(4):705-718. doi: 10.1007/s40618-021-01705-2. Epub 2021 Nov 13.